Rasha E.: Exploring Polycythemia Vera – Beyond the Hematocrit
Rasha E., Senior Clinical Pharmacist and Pharmacy Training Program Director at Abu Dhabi Stem Cells Center (ADSCC), shared a post on LinkedIn:
“Polycythemia Vera (PV): Beyond the Hematocrit
A valuable review from Hemostasis Today highlighting an important aspect of Polycythemia Vera management: thrombosis prevention requires more than simply treating the acute event.
PV is a chronic myeloproliferative neoplasm associated with a significant risk of both arterial and venous thrombosis.
Key clinical takeaways:
- Maintaining hematocrit <45% remains a cornerstone of thrombosis prevention.
- Following VTE, anticoagulation should be individualized according to the clinical scenario and patient-specific bleeding/thrombotic risks.
- The need for concomitant aspirin should be carefully reassessed when therapeutic anticoagulation is initiated.
- Appropriate cytoreductive therapy plays an important role in high-risk patients and secondary prevention.
- Unexplained splanchnic vein thrombosis should prompt consideration of an underlying myeloproliferative neoplasm, including JAK2-mutated PV.
- Emerging therapies such as rusfertide may offer additional options for controlling erythrocytosis and reducing phlebotomy requirements.
My takeaway:
The goal is not simply to treat the clot – it is to control the underlying disease, reduce recurrent thrombotic risk, and optimize long-term outcomes.
This is where multidisciplinary collaboration between hematology, clinical pharmacy, and thrombosis specialists can make a meaningful difference.
An excellent resource for clinicians managing patients with PV and thrombotic complications.
Source: Hemostasis Today – Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera.”
Stay updated with Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP